MBB Public Markets I LLC Makes New Investment in UiPath Inc. (NYSE:PATH)

MBB Public Markets I LLC acquired a new position in UiPath Inc. (NYSE:PATH) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 27,548 shares of the healthcare company’s stock, valued at approximately $349,000.

A number of other hedge funds also recently modified their holdings of the company. APG Asset Management N.V. lifted its position in shares of UiPath by 171.2% in the 2nd quarter. APG Asset Management N.V. now owns 57,500 shares of the healthcare company’s stock worth $680,000 after acquiring an additional 36,300 shares during the period. AQR Capital Management LLC lifted its position in shares of UiPath by 120.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,633,393 shares of the healthcare company’s stock worth $20,385,000 after buying an additional 892,845 shares during the period. Armistice Capital LLC lifted its position in shares of UiPath by 94.9% during the 2nd quarter. Armistice Capital LLC now owns 726,520 shares of the healthcare company’s stock worth $9,212,000 after buying an additional 353,781 shares during the period. AXA S.A. lifted its position in shares of UiPath by 89.9% during the 2nd quarter. AXA S.A. now owns 53,016 shares of the healthcare company’s stock worth $672,000 after buying an additional 25,094 shares during the period. Finally, Toronto Dominion Bank lifted its position in shares of UiPath by 15.4% during the 2nd quarter. Toronto Dominion Bank now owns 42,654 shares of the healthcare company’s stock worth $541,000 after buying an additional 5,704 shares during the period. Institutional investors own 62.50% of the company’s stock.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $12.07, for a total value of $575,388.97. Following the transaction, the chief financial officer now directly owns 849,917 shares in the company, valued at approximately $10,258,498.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.37% of the stock is owned by corporate insiders.

UiPath Stock Performance

NYSE PATH opened at $12.32 on Thursday. The stock has a fifty day moving average of $12.18 and a 200-day moving average of $15.27. The stock has a market capitalization of $6.78 billion, a P/E ratio of -77.00 and a beta of 0.87. UiPath Inc. has a 52 week low of $10.37 and a 52 week high of $27.87.

UiPath (NYSE:PATH) last released its earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The company had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. During the same period last year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. Equities research analysts forecast that UiPath Inc. will post -0.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on PATH. DA Davidson raised their target price on UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. Royal Bank of Canada restated a “sector perform” rating and set a $16.00 target price on shares of UiPath in a research report on Friday, September 6th. Morgan Stanley restated an “equal weight” rating and set a $15.00 target price on shares of UiPath in a research report on Friday, September 6th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research report on Friday, September 6th. Finally, Wells Fargo & Company raised their price target on UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a report on Friday, September 6th. Sixteen analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $17.71.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.